NBRV News and Press, Nabriva Therapeutics plc From 08/18/19

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Podcast listener? Subscribe now to receive Wall Street Breakfast by 8:00 a.m. every t...

Based on feedback from the FDA and the receipt of the minutes from its meeting with the agency, Nabriva Therapeutics (NASDAQ: NBRV ) expects to resubmit its marketing application next quarter for CONTEPO (fosfomycin) for the treatment of complicated urinary tract infections, including acut...

DUBLIN, Ireland, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that following its receipt of final Type A Meeti...

Paratek Pharmaceuticals ( PRTK ) reported earnings on Tuesday, August 6, with the stock trading up over 30% in response to the report and then running further throughout the rest of the week. I find the numbers from the launch of Nuzyra (omadacycline), however, to be less than encouraging. I...

Nabriva Therapeutics (NASDAQ: NBRV ): Q2 GAAP EPS of -$0.44. More news on: Nabriva Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and six months ended June 3...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Chief Commercial Officer Francesc...

WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...

WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...